SAN JOSE, Calif., Oct. 28, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ('Anixa' or the 'Company') (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of additional data from the Phase 1 clinical trial of its breast cancer vaccine at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held virtually and in Houston, Texas, from November 6-10, 2024.

加利福尼亚州圣何塞，2024年10月28日/PRNewswire/--专注于癌症治疗和预防的生物技术公司Anixa Biosciences，Inc.（“Anixa”或“公司”）（纳斯达克：ANIX）今天宣布，将于2024年11月6日至10日在德克萨斯州休斯顿举行的癌症免疫治疗学会（SITC）第39届年会上公布其乳腺癌疫苗第一阶段临床试验的额外数据。

The trial is being conducted in collaboration with Cleveland Clinic with funding by a grant from the U.S. Department of Defense. The presentation, titled 'Phase I Trial of alpha-lactalbumin vaccine in high risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC,' will be presented by Dr.

该试验是与克利夫兰诊所合作进行的，由美国国防部拨款资助。这篇题为“α-乳清蛋白疫苗在高风险可手术三阴性乳腺癌（TNBC）和TNBC高遗传风险患者中的I期试验”的演讲将由Dr。

Emily Rhoades, FDA/IND Trial Program Manager at Cleveland Clinic..

克利夫兰诊所FDA/IND试验项目经理Emily Rhoades。。

Details of the poster presentation can be found below:

海报展示的详细信息可以在下面找到：

Poster Title:  Phase I Trial of alpha-lactalbumin vaccine in high risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC

海报标题：α-乳清蛋白疫苗在高危可手术三阴性乳腺癌（TNBC）和TNBC高遗传风险患者中的I期试验

Abstract #: 631

摘要#：631

Date/Time: November 8, 2024, 12:15 p.m. CT

日期/时间：2024年11月8日，康涅狄格州下午12:15

After the data is presented, Anixa will make the poster presentation available on its website and through a public announcement.

数据发布后，Anixa将在其网站上通过公告发布海报。

About Anixa Bioscience's Breast Cancer VaccineAnixa's breast cancer vaccine takes advantage of endogenously produced proteins that have a function at certain times in life, but then become 'retired' and disappear from the body. One such protein is a breast-specific lactation protein, α-lactalbumin, which is no longer found post-lactation in normal, aging tissues, but is present in certain breast cancers.

关于Anixa Bioscience的乳腺癌疫苗Anixa的乳腺癌疫苗利用内源性产生的蛋白质，这些蛋白质在生命的某些时候具有功能，但随后会“退休”并从体内消失。其中一种蛋白质是乳腺特异性泌乳蛋白α-乳清蛋白，在正常的衰老组织中泌乳后不再发现，但存在于某些乳腺癌中。

Activating the immune system against this 'retired' protein provides preemptive immune protection against emerging breast tumors that express α-lactalbumin. The vaccine also contains an adjuvant that activates an innate immune response, which allows the immune system to mount a response against emerging tumors to prevent them from growing..

激活针对这种“退役”蛋白的免疫系统，可以针对表达α-乳清蛋白的新兴乳腺肿瘤提供先发制人的免疫保护。。。

Initial Phase 1 data was presented at the San Antonio Breast Cancer Symposium in December 2023. The data showed no safety concerns, with protocol defined immune responses observed in a majority of patients.

最初的第一阶段数据于2023年12月在圣安东尼奥乳腺癌研讨会上发表。数据显示没有安全问题，在大多数患者中观察到方案定义的免疫反应。

The Phase 1 trial is conducted in collaboration with Cleveland Clinic and is funded by a grant from the U.S. Department of Defense. Anixa is the exclusive worldwide licensee of the novel breast cancer vaccine technology developed at Cleveland Clinic. The grant funding from the U.S. Department of Defense was provided to Cleveland Clinic..

。Anixa是克利夫兰诊所开发的新型乳腺癌疫苗技术的全球独家许可证持有人。美国国防部的拨款提供给克利夫兰诊所。。

This vaccine technology was invented by the late Dr. Vincent Tuohy, who was the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research in the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. Cleveland Clinic exclusively licensed this technology to Anixa Biosciences.

这种疫苗技术是由已故的Vincent Tuohy博士发明的，他是克利夫兰诊所勒纳研究所炎症与免疫系创新乳腺癌研究的Mort and Iris-Novel杰出主席。克利夫兰诊所将该技术独家许可给Anixa Biosciences。

The Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company..

克利夫兰诊所有权从公司获得特许权使用费和其他商业化收入。。

About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology.

关于Anixa Biosciences，Inc.Anixa是一家临床阶段生物技术公司，专注于癌症的治疗和预防。Anixa的治疗组合包括与Moffitt癌症中心合作开发的卵巢癌免疫治疗计划，该计划使用一种新型CAR-T，称为嵌合内分泌受体-T细胞（CER-T）技术。

The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate.

该公司的疫苗组合包括与克利夫兰诊所合作开发的用于治疗和预防乳腺癌和卵巢癌的疫苗，以及用于治疗许多难治性癌症的其他癌症疫苗，包括肺癌，结肠癌和前列腺癌的高发恶性肿瘤。

These vaccine technologies focus on immunizing against 'retired' proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization.

这些疫苗技术的重点是针对已发现在某些形式的癌症中表达的“退役”蛋白质进行免疫。Anixa在各个发展阶段与世界知名研究机构合作的独特商业模式使公司能够不断研究互补领域的新兴技术，以进一步开发和商业化。

To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube..

要了解更多信息，请访问www.anixa.com或在Twitter、LinkedIn、Facebook和YouTube上关注anixa。。

Forward-Looking StatementsStatements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results.

前瞻性陈述非历史事实的陈述可被视为1995年《私人证券诉讼改革法案》所指的前瞻性陈述。前瞻性陈述不是对历史事实的陈述，而是反映了安妮莎目前对未来事件和结果的期望。

We generally use the words 'believes,' 'expects,' 'intends,' 'plans,' 'anticipates,' 'likely,' 'will' and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.

我们通常使用“相信”、“期望”、“打算”、“计划”、“预期”、“可能”、“意志”等词语来识别前瞻性陈述。此类前瞻性声明，包括与我们的预期有关的声明，涉及风险、不确定性和其他因素，其中一些因素超出了我们的控制范围，这可能导致我们的实际结果、业绩或成就或行业结果与此类前瞻性声明明示或暗示的任何未来结果、业绩或成就存在重大差异。

These risks, uncertainties and factors include, but are not limited to, those factors set forth in 'Item 1A - Risk Factors' and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

这些风险、不确定性和因素包括但不限于“第1A项-风险因素”和我们最近的10-K表年度报告其他章节以及10-Q表季度报告和8-K表当前报告中规定的因素。除法律要求外，我们没有义务公开更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因。

You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release..

在评估本新闻稿中提供的信息时，请注意不要过度依赖此类前瞻性声明。。

Contact:Mike CatelaniPresident, COO & CFOmcatelani@anixa.com408-708-9808

联系人：Mike Catelani总裁兼首席运营官&CFOmcatelani@anixa.com408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-and-cleveland-clinic-to-present-additional-data-from-phase-1-study-of-breast-cancer-vaccine-at-the-39th-society-for-immunotherapy-of-cancer-sitc-annual-meeting-302288176.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/anixa-biosciences-and-cleveland-clinic-to-present-additional-data-from-phase-1-study-of-breast-cancer-vaccine-at-the-39th-society-for-immunotherapy-of-cancer-sitc-annual-meeting-302288176.html

SOURCE Anixa Biosciences, Inc.

来源Anixa Biosciences，Inc。